Abstract
The chapter focuses on the mechanisms through which the serotoninergic system can induce hallucinations, altering sensory perceptive functions. The hallucinogenic activity of the serotoninergic receptors has been noticed since perceptual alterations induced by the consumption of some recreational drugs, such as LSD and ecstasy, were observed. Hallucinogenic effects and specific molecular mechanisms of action are discussed in this chapter. Hallucinogens and entactogens can both produce hallucinations through an increase of the serotoninergic pathway activity, which is thought to be one of the pathophysiological processes underlying positive symptoms. LSD and MDMA seem to act with a different molecular mechanism. The main molecular effect of classical hallucinogens consists of increasing 5-HT brain levels, since they act as 5-HT receptor agonists. 5-HT2A receptors, mainly localized in medial prefrontal cortex, thalamic reticular nucleus, locus coeruleus and raphe nucleus, seem to be the most important hallucinogenic target, even if it has been demonstrated that 5-HT2C receptors could also be required. Hallucinogens therefore alter ascending sensory information processed through the thalamus. This could be mediated through alterations in different systems leading to a sensorial information overload. Classical hallucinogens should be considered as potent modulators of cortex network activity through the augmented 5-HT2A agonist activity in the medial prefrontal cortex, the reduced inhibitory activity by thalamic reticular nucleus, the altered firing of raphe nucleus, and the increased activity in the locus coeruleus. Entactogens seem to act increasing intracellular and extracellular 5-HT levels by inhibiting the SERT activity, reversing its action through TAAR1 agonism, inhibiting VMAT2, and inhibiting the MAO enzymes. Entactogens also act on NET, and to a lesser extent on DAT. The hallucinogenic effect of entactogens is probably also due to a partial agonist activity on 5-HT2A activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hoffer A, Osmond H, Smythies J. Schizophrenia: a new approach. II. Results of a year’s research. J Ment Sci. 1954;100:29–45.
Hollister LE. Drug-induced psychoses and schizophrenic reactions, a critical comparison. Ann N Y Acad Sci. 1962;96:80–8.
Hollister LE. Chemical psychoses: LSD and related drugs. Springfield, IL: Thomas; 1968.
Glennon RA. Classical drugs: an introductory overview. In: Lin GC, Glennon RA, editors. Hallucinogens: an update. Rockville, MD: National Institute on Drug Abuse; 1994.
Nichols DE, Glennon RA. Medicinal chemistry and structure-activity relationships of hallucinogens. In: Jacobs BL, editor. Hallucinogens: neurochemical, behavioral, and clinical perspectives. New York: Raven Press; 1984. p. 95–142.
Ludwig AM. Altered states of consciousness. Arch Gen Psychiatry. 1966;15:225–34.
Preller KH, Vollenweider FX. Phenomenology , structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. 2018;36:221–56.
Díaz JL. Sacred plants and visionary consciousness. Phenomenol Cogn Sci. 2010;9(2):159–70.
Schmid Y, Enzler F, Gasser P, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544–53.
Studerus E, Kometer M, Hasler F, et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25:1434–52.
Rolland B, Jardri R, Amad A, et al. Pharmacology of hallucinations: several mechanisms for one single symptom? BioMed Res Int. 2014;2014, Article ID 307106, 9 p.
Campbell RJ. Psychiatric dictionary. 6th ed. New York: Oxford University Press; 1989.
Anden NE, Corrodi H, Fuxe K, Hokfelt T. Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide. Br J Pharmacol. 1968;34:1–7.
Anden NE, Corrodi H, Fuxe K. Hallucinogenic drugs of the indolcalkylamine type and central monoamine neurons. J Pharmacol Exp Ther. 1971;179:236–49.
Randic M, Padjen A. Effect of N,N-dimethyltryptamine and D-lysergic acid diethylamide on the release of 5-hydroxyindoles in rat forebrain. Nature. 1971;230:532–3.
Fuxe K, Holmstedt B, Jonsson G. Effects of 5-methoxy-N,N-dimethyltrypstamine on central monoamine neurons. Eur J Pharmacol. 1972;19:25–34.
Glennon RA, Young R, Rosecrans JA. Antagonism of the stimulus effects of the hallucinogen DOM and the purported serotonin agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol. 1983;91:189–92.
Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505–11.
Colpaert FC, Janssen PA. A characterization of LSD-antagonist effects of pirenperone in the rat. Neuropharmacology. 1983;22:1001–5.
Colpaert FC, Niemegeers CJ, Janssen PA. A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD-antagonist. J Pharmacol Exp Ther. 1982;221:206–14.
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897–902.
Nichols D. Hallucinogens. Pharmacol Ther. 2004;101:131–81.
Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32:225–32.
Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642–51.
Aghajanian GK, Marek GJ. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropsychopharmacology. 1997;36:589–99.
Aghajanian GK, Marek GJ. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 1999;825:161–71.
Marek GJ, Wright RA, Gewirtz JC, et al. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience. 2001;105:379–92.
Beique JC, Imad M, Mladenovic L, et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A. 2007;104:9870–5.
Puig MV, Celada P, az-Mataix L, et al. In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex. 2003;13:870–82.
Gonzalez-Maeso J, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–52.
Marek GJ, Wright RA, Schoepp DD, et al. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 2000;292:76–87.
Moorman JM, Leslie RA. p-Chloroamphetamine induces c-fos in rat brain: a study of serotonin 2A/2C receptor function. Neuroscience. 1996;72:129–39.
Scruggs JL, Patel S, Bubser M, et al. DOI-induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons. J Neurosci. 2000;20:8846–52.
Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain: IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987;21:123–39.
Wong DF, Lever JR, Hartig PR, et al. Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-BR-LSD. Synapse. 1987;1:393–8.
Jakab RL, Goldman-Rakic PS. 5-HT2A serotonin in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci U S A. 1998;95:735–40.
Xia Z, Gray JA, Compton-Toth BA, et al. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction. J Biol Chem. 2003;278:21901–8.
Celada P, Puig MV, Casanovas JM, et al. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J Neurosci. 2001;21:9917–29.
Vazquez-Borsetti P, Cortes R, Artigas F. Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex. 2009;19:1678–86.
Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C] raclopride. Neuropsychopharmacology. 1999;20:424–33.
Moreno JL, Holloway T, Albizu L, et al. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptors agonists. Neurosci Lett. 2011;493:76–9.
Crick F. Function of the thalamic reticular complex: the searchlight hypothesis. Proc Natl Acad Sci U S A. 1984;81:4586–90.
Pinault D. The thalamic reticular nucleus: structure, function and concept. Brain Res Brain Res Rev. 2004;46:1–31.
Yingling CD, Skinner JE. Selective regulation of thalamic sensory relay nuclei by nucleus reticularis thalami. Electroencephalogr Clin Neurophysiol. 1976;41:476–82.
Guillery RW, Sherman SM. Thalamic relay functions and their role in corticocortical communication: generalizations from the visual system. Neuron. 2002;33:163–75.
Guillery RW, Feig SL, Lozsadi DA. Paying attention to the thalamic reticular nucleus. Trends Neurosci. 1998;21:28–32.
Golomb D, Ahissar E, Kleinfeld D. Coding of stimulus frequency by latency in thalamic networks through the interplay of GABAB-mediated feedback and stimulus shape. J Neurophysiol. 2006;95:1735–50.
McAlonan K, Cavanaugh J, Wurtz RH. Attentional modulation of thalamic reticular neurons. J Neurosci. 2006;26:4444–50.
McAlonan K, Cavanaugh J, Wurtz RH. Guarding the gateway to cortex with attention in visual thalamus. Nature. 2008;456:391–4.
Yu XJ, Xu XX, He S, et al. Change detection by thalamic reticular neurons. Nat Neurosci. 2009;12:1165–70.
Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull. 2001;56:495–507.
Nestler EJ, Alreja M, Aghajanian GK. Molecular control of locus coeruleus neurotransmission. Biol Psychiatry. 1999;46:1131–9.
Rasmussen K, Aghajanian GK. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res. 1986;385:395–400.
Chiang C, Aston-Jones G. A 5-hydroxytryptamine 2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience. 1993;54:409–20.
Rasmussen K, Glennon RA, Aghajanian GK. Phenethyl-amine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity. Eur J Pharmacol. 1986;132:79–82.
Marek GJ, Aghajanian GK. Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend. 1998;51:189–98.
Araneda R, Andrade R. 5-Hydroxytryptamine 2 and 5-hydroxy-tryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience. 1991;40:399–412.
Behrendt RP. Hallucinations: synchronization of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn. 2003;12:413–51.
Tilakaratne N, Friedman E. Genomic responses to 5-HT1a or 5-HT2a2c receptor activation is differentially regulated in four regions of rat brain. Eur J Pharmacol. 1996;307:211–7.
Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology. 2002;26:634–42.
Leslie RA, Moorman JM, Coulson A, et al. Serotonin 2/1 C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibers. Neuroscience. 1993;53:457–63.
Nichols CD, Garcia EE, Sanders-Bush E. Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Mol Brain Res. 2003;111:182–8.
Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol. 1984;106:539–46.
Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 1988;94:213–6.
Parker MA, Marona-Lewicka D, Lucaites VL, et al. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem. 1998;41:5148–9.
Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, et al. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. J Med Chem. 2001;44:1003–10.
Burris KD, Breeding M, Sanders-Bush E. (+) Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J Pharmacol Exp Ther. 1991;258:891–6.
Fiorella D, Rabin RA, Winter JC. Role of 5-HT 2A and 5-HT 2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives. Psychopharmacology. 1995;121:357–63.
Sanders-Bush E. Neurochemical evidence that hallucinogenic drugs are 5-HT1C receptor agonists: what next? NIDA Res Monogr. 1994;146:203–13.
Glennon RA, Hauck AE. Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav. 1985;23:937–41.
Glennon RA. Do hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology. 1990;56:509–17.
Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs. 1986;18:305–13.
Hysek CM, Schmid Y, Simmler LD, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645–52.
Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012;86:1167–231.
Kleven MS, Seiden LS. Methamphetamine-induced neurotoxicity: structure activity relationships. Ann N Y Acad Sci. 1992;654:292–301.
Freudenmann RW, Öxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006;101:1241–5.
Rugani F, Bacciardi S, Rovai L, et al. Symptomatological features of patients with and without ecstasy use during their first psychotic episode. Int J Environ Res Public Health. 2012;9:2283–92.
United Nations Office on Drugs and Crime UNODC World Drug Report. United Nations publication, Sales No. E16XI7. 2016.
Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. Can Med Assoc J. 2001;165:917–28.
Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol Clin Exp. 2001;16:557–77.
Schifano F. Chronic atypical psychosis associated with MDMA. Lancet. 1991;338:1335.
Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”). Prog Neuro-Psychopharmacol Biol Psychiatry. 1997;21:727–34.
Keenan E, Gervin M, Dorman A, O'Connor JJ. Psychosis and recreational use of MDMA (“Ecstasy”). Ir J Psychol Med. 1993;10:162–3.
Boné PI, Ramos GP, Villalba YP, et al. Persisting and late onset psychotic disorder due to consumption of ecstasy (MDMA). Actas Esp Psiquiatr. 1999;28:61–5.
Landabaso MA, Iraurgi I, Jiménez-Lerma JM, et al. Ecstasy-induced psychotic disorder: six-month follow-up study. Eur Addict Res. 2002;8:133–40.
Potash MN, Gordon KA, Conrad KL. Persistent psychosis and medical complications after a single ingestion of MDMA “Ecstasy”: a case report and review of the literature. Psychiatry. 2009;6:40.
Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). JAMA. 1987;258:780–1.
Creighton FJ, Black DL, Hyde CE. 'Ecstasy' psychosis and flashbacks. Br J Psychiatry. 1991;159:713–5.
Vollenweider FX. Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci. 2001;3:265–80.
Davison D, Parrott AC. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol Clin Exp. 1997;12:221–6.
Oliveri M, Calvo G. Increased visual cortical excitability in ecstasy users: a transcranial magnetic stimulation study. J Neurol Neurosurg Psychiatry. 2003;74:1136–8.
Hanck L, Schellekens AF. Hallucinogen persisting perception disorder after ecstasy use. Ned Tijdschr Geneeskd. 2012;157:A5649.
Robbins TW, Everitt BJ. Drug addiction: bad habits add up. Nature. 1999;398:567–70.
Parrott AC, Sisk E, Turner JJD. Psychobiological problems in heavy ‘ecstasy’(MDMA) polydrug users. Drug Alcohol Depend. 2000;60:105–10.
Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”). Psychopharmacology. 1995;119:247–60.
Koch S, Galloway MP. MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm. 1997;104:135–46.
O'Loinsigh ED, Boland G, Kelly JP, et al. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25:621–38.
Mechan AO, Esteban B, O'Shea E, et al. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. Br J Pharmacol. 2002;135:170–80.
Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology. 2007;189:489–503.
Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003;479:23–40.
Clauwaert KM, Van Bocxlaer JF, Els A, et al. Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine. Clin Chem. 2000;46:1968–77.
Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55:463–508.
de Win MM, Jager G, Booij J, Reneman L, et al. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain. 2008;131:2936–45.
Parrott AC. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans—no need for translation. Br J Pharmacol. 2012;166:1518–20.
Meyer JS. 3,4-Methylenedioxymethamphetamine (MDMA): current perspectives. Subst Abuse Rehabil. 2013;4:83–99.
Berger UV, Gu XF, Azmitia EC. The substituted amphetamines 3, 4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol. 1992;215:153–60.
Mørland J. Toxicity of drug abuse—amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Toxicol Lett. 2000;112:147–52.
Gudelsky GA, Nash JF. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem. 1996;66:243–9.
Tao R, Shokry IM, Callanan JJ, et al. Mechanisms and environmental factors underlying the intensification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced serotonin syndrome in rats. Psychopharmacology. 2015;232:1245–60.
Hagino Y, Takamatsu Y, Yamamoto H, et al. Effects of MDMA on extracellular dopamine and serotonin levels in mice lacking dopamine and/or serotonin transporters. Curr Neuropharmacol. 2011;9:91–5.
Liechti ME, Baumann C, Gamm A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000a;22:513–21.
Liechti ME, Saur MR, Gamma A, et al. Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000b;23:396–404.
Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology. 1998;136:409–14.
Kometer M, Schmidt A, Jäncke L, et al. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33:10544–51.
Sadzot B, Baraban JM, Glennon RA, et al. Hallucinogenic drug interactions at human brain 5-HT 2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology. 1989;98:495–9.
Mlinar B, Mascalchi S, Morini R, et al. MDMA induces EPSP-spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and β1 receptors. Neuropsychopharmacology. 2008;33:1464–75.
Oleskevich S, Descarries L. Quantified distribution of the serotonin innervation in adult rat hippocampus. Neuroscience. 1990;34:19–33.
Oleskevich S, Descarries L, Lacaille JC. Quantified distribution of the noradrenaline innervation in the hippocampus of adult rat. J Neurosci. 1989;9:3803–15.
Hensler JG. Serotonergic modulation of the limbic system. Neurosci Biobehav Rev. 2006;30:203–14.
Gamma A, Buck A, Berthold T, et al. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans. Neuropsychopharmacology. 2000;23:388–95.
Litjens RP, Brunt TM, Alderliefste GJ, et al. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol. 2014;24:1309–23.
Greene SL, Dargan PI, O’Connor N, et al. Multiple toxicity from 3, 4-methylenedioxymethamphetamine (“ecstasy”). Am J Emerg Med. 2003;21:121–4.
Segura M, Farré M, Pichini S, et al. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans. Clin Pharmacokinet. 2005;44:649–60.
Roiser JP, Cook LJ, Cooper JD, et al. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am J Psychiatr. 2005;162:609–12.
Roiser JP, Rogers RD, Cook LJ, et al. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. Psychopharmacology. 2006;188:213–27.
Acknowledgments
This chapter was supported by a grant from the AIFA (Proposal AIFA-2016-02364852). pathway involved in substance-induced hallucinations.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Lazzaretti, M., Mandolini, G.M., Altamura, A.C., Brambilla, P. (2018). Substances of Abuse and Hallucinogenic Activity: The Serotoninergic Pathway - Focus on Classical Hallucinogens and Entactogens. In: Brambilla, P., Mauri, M., Altamura, A. (eds) Hallucinations in Psychoses and Affective Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-75124-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-75124-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-75123-8
Online ISBN: 978-3-319-75124-5
eBook Packages: MedicineMedicine (R0)